Ads
related to: pfizer 2023 earnings report transcriptinsights.pfizer.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street consensus estimates of $62.9 billion, and earnings per share of $3.12 ...
PFE earnings call for the period ending December 31, 2024. ... Our assumptions for 2025 are on par with these 2023 and 2024 patterns. And with the multi-year contracts we have secured in ...
The company, raised its full-year guidance by $1.5 billion and beat Wall Street estimates in its third quarter earnings Tuesday. Pfizer now expects between $61 billion and $64 billion in revenue ...
Image source: The Motley Fool. Pfizer (NYSE: PFE) Q3 2024 Earnings Call Oct 29, 2024, 10:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
An earnings call is a teleconference, or webcast, in which a public company discusses the financial results of a reporting period ("earnings guidance"). The name comes from earnings per share (EPS), the bottom line number in the income statement divided by the number of shares outstanding.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
For premium support please call: 800-290-4726 more ways to reach us
In March 2023, Pfizer agreed to acquire Seagen for a total enterprise value of around $43 billion. The acquisition includes the FDA approved medicines Adcetris for lymphomas, Padcev for bladder cancers, Tivdak for cervical cancer and Tukysa for breast and colorectal cancers as well as Seagen's drug development pipeline.